{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T06:01:55Z","timestamp":1789970515896,"version":"4.0.1"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82303013"],"award-info":[{"award-number":["82303013"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82203551"],"award-info":[{"award-number":["82203551"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014175","name":"Shanghai Municipal Health and Family Planning Commission","doi-asserted-by":"publisher","award":["20244Y0193"],"award-info":[{"award-number":["20244Y0193"]}],"id":[{"id":"10.13039\/501100014175","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The tryptophan metabolite 3-hydroxyanthranilic acid (3-HAA) has been reported to exert tumor-growth-inhibitory activity; however, its functional role and underlying mechanisms in colorectal cancer (CRC) remain largely unexplored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We measured 3-HAA levels in CRC tissues and evaluated its effects on CRC cell proliferation through exogenous administration. Mechanistic investigations were performed to identify its direct protein targets and downstream signaling pathways. The therapeutic potential of 3-HAA, alone and in combination with 5-fluorouracil (5-FU), was assessed both\n                      <jats:italic>in vitro<\/jats:italic>\n                      and\n                      <jats:italic>in vivo<\/jats:italic>\n                      using cell line-derived xenograft mouse model and AOM\/DSS-induced colorectal tumor mouse model.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      3-HAA exhibited depleted levels in CRC tissues, and its exogenous administration effectively suppressed the proliferation of multiple CRC cell lines. Through its binding to the Yin Yang 1 (YY1) transcription factor, it disrupted the YY1-p53 interaction, preserved p53 stability, and induced cell cycle arrest. Notably,\n                      <jats:italic>in vitro<\/jats:italic>\n                      , 3-HAA reduced chemoresistance to the common CRC-chemotherapy drug 5-fluorouracil (5-FU) via the YY1-DKK4 axis. Consistently,\n                      <jats:italic>in vivo<\/jats:italic>\n                      , combined 3-HAA-5-FU treatment effectively inhibited CRC progression.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Our findings demonstrate that 3-HAA functions as a tumor suppressor in CRC by targeting the YY1\u2013p53 axis and enhancing chemosensitivity to 5-FU. These results highlight the potential of 3-HAA as a promising therapeutic agent for CRC treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1928654","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T05:35:38Z","timestamp":1789968938000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["3-hydroxyanthranilic acid suppresses colorectal cancer growth and enhances 5-fluorouracil sensitivity via the YY1-p53 and YY1-DKK4 axes"],"prefix":"10.3389","volume":"17","author":[{"given":"Guifang","family":"Gan","sequence":"first","affiliation":[{"name":"Department of Clinical Laboratory Medicine, Shanghai Ninth People\u2019s Hospital, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengfang","family":"Shangguan","sequence":"additional","affiliation":[{"name":"Department of Oncology, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Pathology, Shanghai Ninth People\u2019s Hospital, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suoyu","family":"Xiang","sequence":"additional","affiliation":[{"name":"Basic Medical Institute, Key Laboratory of Cell Differentiation and Apoptosis of the Chinese Ministry of Education, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaopeng","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Histoembryology, Genetics and Developmental Biology, Key Laboratory of Cell Differentiation and Apoptosis of the Chinese Ministry of Education, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1687556","DOI":"10.3389\/fmolb.2025.1687556","article-title":"Immunological landscape of colorectal cancer: tumor microenvironment, cellular players and immunotherapeutic opportunities","volume":"12","author":"Andac-Aktas","year":"2025","journal-title":"Front. Mol. Biosci."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1178646917691938","DOI":"10.1177\/1178646917691938","article-title":"Kynurenine pathway of tryptophan metabolism: regulatory and functional aspects","volume":"10","author":"Badawy","year":"2017","journal-title":"Int. J. Tryptophan Res."},{"key":"B3","doi-asserted-by":"publisher","first-page":"eaaf9794","DOI":"10.1126\/science.aaf9794","article-title":"Kynurenines: tryptophan's metabolites in exercise, inflammation, and mental health","volume":"357","author":"Cervenka","year":"2017","journal-title":"Science"},{"key":"B4","doi-asserted-by":"publisher","first-page":"8338","DOI":"10.1038\/s41467-023-43527-1","article-title":"On the benefits of the tryptophan metabolite 3-hydroxyanthranilic acid in Caenorhabditis elegans and mouse aging","volume":"14","author":"Dang","year":"2023","journal-title":"Nat. Commun."},{"key":"B5","doi-asserted-by":"publisher","first-page":"51","DOI":"10.4137\/ijtr.s4282","article-title":"On the biological importance of the 3-hydroxyanthranilic acid: anthranilic acid ratio","volume":"3","author":"Darlington","year":"2010","journal-title":"Int. J. Tryptophan Res."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1016\/S0140-6736(19)32319-0","article-title":"Colorectal cancer","volume":"394","author":"Dekker","year":"2019","journal-title":"Colorectal Cancer Lancet"},{"key":"B7","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1056\/NEJMoa1009473","article-title":"TFAP2E-DKK4 and chemoresistance in colorectal cancer","volume":"366","author":"Ebert","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"118741","DOI":"10.1016\/j.biopha.2025.118741","article-title":"Exploring and bypassing resistance to targeted therapies in colorectal cancer","volume":"193","author":"Favier","year":"2025","journal-title":"Biomed. Pharmacother."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1136\/gutjnl-2023-329543","article-title":"Lactobacillus gallinarum-derived metabolites boost anti-PD1 efficacy in colorectal cancer by inhibiting regulatory T cells through modulating IDO1\/Kyn\/AHR axis","volume":"72","author":"Fong","year":"2023","journal-title":"Gut"},{"key":"B10","doi-asserted-by":"publisher","first-page":"5933","DOI":"10.1128\/mcb.16.10.5933","article-title":"YY1 and NF1 both activate the human p53 promoter by alternatively binding to a composite element, and YY1 and E1A cooperate to amplify p53 promoter activity","volume":"16","author":"Furlong","year":"1996","journal-title":"Mol. Cell Biol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/s41420-021-00561-6","article-title":"3-hydroxyanthranic acid increases the sensitivity of hepatocellular carcinoma to sorafenib by decreasing tumor cell stemness","volume":"7","author":"Gan","year":"2021","journal-title":"Cell Death Discov."},{"key":"B12","doi-asserted-by":"publisher","first-page":"12165","DOI":"10.1073\/pnas.0402283101","article-title":"YY1 inhibits the activation of the p53 tumor suppressor in response to genotoxic stress","volume":"101","author":"Gronroos","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B13","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s00262-024-03925-w","article-title":"IDO1 inhibitor enhances the effectiveness of PD-1 blockade in microsatellite stable colorectal cancer by promoting macrophage pro-inflammatory phenotype polarization","volume":"74","author":"Guangzhao","year":"2025","journal-title":"Cancer Immunol. Immunother."},{"key":"B14","doi-asserted-by":"publisher","first-page":"3340","DOI":"10.1091\/mbc.e07-02-0173","article-title":"Cdc6 stability is regulated by the Huwe1 ubiquitin ligase after DNA damage","volume":"18","author":"Hall","year":"2007","journal-title":"Mol. Biol. Cell"},{"key":"B15","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/1758834015614530","article-title":"Pharmacologic resistance in colorectal cancer: a review","volume":"8","author":"Hammond","year":"2016","journal-title":"Ther. Adv. Med. Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/postmj\/qgad136","article-title":"Immunotherapy of microsatellite stable colorectal cancer: resistance mechanisms and treatment strategies","volume":"100","author":"Han","year":"2024","journal-title":"Postgrad. Med. J."},{"key":"B17","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/179663a0","article-title":"Fluorinated pyrimidines, a new class of tumour-inhibitory compounds","volume":"179","author":"Heidelberger","year":"1957","journal-title":"Nature"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1002\/cncr.25666","article-title":"DICKKOPF-4 activates the noncanonical c-Jun-NH2 kinase signaling pathway while inhibiting the Wnt-canonical pathway in human renal cell carcinoma","volume":"117","author":"Hirata","year":"2011","journal-title":"Cancer"},{"key":"B19","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1038\/s41401-024-01354-0","article-title":"Aristolochic acids-hijacked p53 promotes liver cancer cell growth by inhibiting ferroptosis","volume":"46","author":"Hou","year":"2025","journal-title":"Acta Pharmacol. Sin."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1016\/j.ajpath.2011.05.048","article-title":"The tryptophan metabolite 3-hydroxyanthranilic acid plays anti-inflammatory and neuroprotective roles during inflammation: role of hemeoxygenase-1","volume":"179","author":"Krause","year":"2011","journal-title":"Am. J. Pathol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1016\/j.ccell.2024.10.013","article-title":"Long-term breast cancer response to CDK4\/6 inhibition defined by TP53-mediated geroconversion","volume":"42","author":"Kudo","year":"2024","journal-title":"Cancer Cell"},{"key":"B22","doi-asserted-by":"publisher","first-page":"5906","DOI":"10.1038\/s41467-025-60958-0","article-title":"Caffeine enhances antitumor T-cell activity by suppressing kynurenine pathway in colorectal cancer","volume":"16","author":"Liu","year":"2025","journal-title":"Nat. Commun."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2786","DOI":"10.1111\/jcmm.16372","article-title":"A literature review on function and regulation mechanism of DKK4","volume":"25","author":"Lou","year":"2021","journal-title":"J. Cell Mol. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1456030","DOI":"10.3389\/fimmu.2024.1456030","article-title":"Metabolic mediators: microbial-derived metabolites as key regulators of anti-tumor immunity, immunotherapy, and chemotherapy","volume":"15","author":"Lu","year":"2024","journal-title":"Front. Immunol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"27257","DOI":"10.1038\/s41598-024-77770-3","article-title":"More subtle microsatellite instability better predicts fluorouracil insensitivity in colorectal cancer patients","volume":"14","author":"Miyashita","year":"2024","journal-title":"Sci. Rep."},{"key":"B26","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41573-019-0016-5","article-title":"Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond","volume":"18","author":"Platten","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"B27","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s13045-021-01165-4","article-title":"Kynurenine derivative 3-HAA is an agonist ligand for transcription factor YY1","volume":"14","author":"Shi","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"e697","DOI":"10.1002\/ctm2.697","article-title":"Kynurenine catabolic enzyme KMO regulates HCC growth","volume":"12","author":"Shi","year":"2022","journal-title":"Clin. Transl. Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"177294","DOI":"10.1016\/j.ejphar.2025.177294","article-title":"Beyond chemotherapy: exploring 5-FU resistance and stemness in colorectal cancer","volume":"991","author":"Singh","year":"2025","journal-title":"Eur. J. Pharmacol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.cell.2004.06.004","article-title":"Yin Yang 1 is a negative regulator of p53","volume":"117","author":"Sui","year":"2004","journal-title":"Cell"},{"key":"B31","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"B32","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1007\/BF01880660","article-title":"New targets for pyrimidine antimetabolites in the treatment of solid tumours. 1: thymidylate synthase","volume":"16","author":"van der Wilt","year":"1994","journal-title":"Pharm. World Sci."},{"key":"B33","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1186\/s12967-026-07758-2","article-title":"IDO family: the metabolic crossroads connecting immunity, nerves and tumors","volume":"24","author":"Wang","year":"2026","journal-title":"J. Transl. Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1186\/s12885-025-15138-0","article-title":"Global burden of colorectal cancer in 2022 and projections to 2050: incidence and mortality estimates from GLOBOCAN","volume":"25","author":"Wu","year":"2025","journal-title":"BMC Cancer"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e2207074","DOI":"10.1002\/advs.202207074","article-title":"Effects of 3-HAA on HCC by regulating the heterogeneous Macrophages-A scRNA-Seq analysis","volume":"10","author":"Xue","year":"2023","journal-title":"Adv. Sci. (Weinh)"},{"key":"B37","doi-asserted-by":"publisher","first-page":"117412","DOI":"10.1016\/j.biopha.2024.117412","article-title":"IDO1 inhibitors are synergistic with CXCL10 agonists in inhibiting colon cancer growth","volume":"179","author":"Yang","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"B38","doi-asserted-by":"publisher","first-page":"115986","DOI":"10.1016\/j.intimp.2025.115986","article-title":"Immune escape in colorectal cancer: mechanisms and challenges of immune checkpoint inhibitor resistance","volume":"169","author":"Yousefi","year":"2026","journal-title":"Int. Immunopharmacol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1662464","DOI":"10.3389\/fcell.2025.1662464","article-title":"Metabolic reprogramming and immunosenescence in colorectal cancer: mechanisms and therapeutic implications","volume":"13","author":"Zhu","year":"2025","journal-title":"Front. Cell Dev. Biol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1928654\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T05:35:38Z","timestamp":1789968938000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1928654\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,21]]},"references-count":38,"alternative-id":["10.3389\/fphar.2026.1928654"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1928654","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,21]]},"article-number":"1928654"}}